MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Status:
Withdrawn
Trial end date:
2023-04-06
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of MM-398 and ramucirumab in
treating patients with gastric cancer or gastroesophageal junction adenocarcinoma. MM-398
contains a chemotherapy drug called irinotecan, which in its active form interrupts cell
reproduction. MM-398 builds irinotecan into a container called a liposome which may be able
to release the medicine slowly over time to reduce side effects and increase its ability to
kill tumor cells. Immunotherapy with monoclonal antibodies, such as ramucirumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor cells to
grow and spread. Giving MM-398 and ramucirumab together may work better in treating patients
with gastric cancer or gastroesophageal junction adenocarcinoma.